Compare Marathon Petroleum Corp (MPC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Sana Biotechnology Inc — how do they compare? Marathon Petroleum Corp trades at $464 (market cap $130.12B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Marathon Petroleum Corp is far larger — about 155.5× Sana Biotechnology Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and Sana Biotechnology Inc for 23 Days on average.
| MPC | SANA | |
|---|---|---|
Market Cap | $130.12B | $836.71M |
Volume | 2,749,647 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $463.34 | $5.92 |
52-Week Low | $162.63 | $2.68 |
Typical Hold Time | 54 Days | 23 Days |
Enterprise Value | $156.64B | $749.96M |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $442.26, up 2.29% today, reflecting strong momentum amid bullish technical signals and recent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a P/E of 16.07, below the sector average. Recent news highlights refining margin strength and positive analyst sentiment, though risks include potential diesel export restrictions and volatile energy markets.
Outlook remains positive with 75.8% of analysts rating it a buy and a consensus price target of $420.30. Key opportunities include elevated refining margins and solid cash flow, while risks involve regulatory uncertainty and cyclical demand pressures. The stock's valuation and growth prospects support a constructive view for investors seeking energy exposure.
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
